Special BIO Asia–Taiwan edition newsletter
2026-07-27 |
| Taiwan BIO Weekly - BIO Asia-Taiwan 2026 Special Edition |
| Global Biopharma Capital Allocation Shifts: Venture Investment Strategies and Cross-Border Valuation Dynamics for Asian Startups 22 July, 2026 The 2026 BIO Asia-Taiwan Investment Summit gathered top-tier investors to evaluate evolving capital allocation trends across the global life sciences sector. Following the post-pandemic capital deployment surge, biotechnology investment has stabilized into a disciplined, fundamentals-driven regime. More... |
| To viral or not to viral: In vivo CAR T debates delivery tech Sign-up required 21 July, 2026 The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T's second revolution. More... |
| Securing Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stage 21 July, 2026 The global pharmaceutical supply chain was a primary strategic focus at BIO Asia-Taiwan 2026, where international health officials, policy makers, and executives addressed systemic vulnerabilities exposed by recent geopolitical disruptions and public health crises. More... |
| Canada and Taiwan Build New Bridges Across AI, Advanced Therapeutics and Precision Health 20 July, 2026 Canada-Taiwan Partnering Forum at BIO Asia-Taiwan 2026 brought together innovators spanning AI-enabled drug discovery, advanced therapeutics, precision health and digital platforms, putting practical collaboration and joint R&D pathways at the center of the conversation. More... |
| Japan Looks Beyond Its Borders to Build the Next Generation of Biotech Innovation 20 July, 2026 From open innovation and regulatory reform to humanized disease models and global biomanufacturing, Japanese life sciences leaders at BIO Asia-Taiwan 2026 outlined how international partnerships are becoming central to the country's evolving biotechnology strategy. More... |
| The Netherlands Positions Itself as Europe's Gateway for Life Sciences Innovation 20 July, 2026 At BIO Asia-Taiwan 2026, leaders from the Netherlands Foreign Investment Agency and European Medicines Agency outlined how regulatory engagement, investment incentives and a connected life sciences ecosystem can help Asian biotech innovators navigate the path into Europe. More... |
| Malaysia Positions Biotechnology as a Bridge Between Asian Innovation and Global Markets 20 July, 2026 At BIO Asia-Taiwan 2026, Malaysian biotechnology leaders spotlighted precision diagnostics, advanced biological research and bio-industrial innovation while making the case for cross-border partnerships as a catalyst for commercial growth. More... |
| India's Life Sciences Proposition Expands from Global Scale to Strategic Innovation 20 July, 2026 At BIO Asia-Taiwan 2026, India showcased an evolving life sciences ecosystem where pharmaceutical manufacturing strength is increasingly converging with biopharma innovation, AI-enabled healthcare, green technologies and state-led investment opportunities. More... |
| Hong Kong Makes Its Case as Asia's Biotech Super-Connector: Capital, Regulation and Scale Converge 20 July, 2026 At BIO Asia-Taiwan 2026, Hong Kong's biotech leaders outlined an increasingly integrated proposition for life sciences companies: global capital, faster regulatory pathways, access to the Greater Bay Area and bespoke government support for enterprises seeking to scale internationally. More... |
| Translational Frontiers in Regenerative Medicine: Navigating Clinical Bottlenecks and Commercial Scale for Advanced Cell Therapies 20 July, 2026 The plenary sessions on regenerative medicine at BIO Asia-Taiwan 2026 convened world-renowned researchers to evaluate the translation of laboratory cell engineering into scalable clinical therapies. As cell-based therapeutics transition into advanced human trials, the global biotechnology sector faces complex engineering, regulatory, and health-economic hurdles. More... |
| MOEA Showcases 10 Biomedical Innovations at BIO Asia-Taiwan 2026 20 July, 2026 The Department of Industrial Technology (DoIT) under Taiwan's Ministry of Economic Affairs (MOEA) today (July 16) unveiled 10 cutting-edge biomedical innovations at BIO Asia-Taiwan 2026, leading a Technology Program Pavilion jointly organized by the Industrial Technology Research Institute (ITRI), the Development Center for Biotechnology (DCB), and the Food Industry Research and Development Institute (FIRDI). The featured technologies span three strategic application areas-regenerative medicine, precision medicine, and high-value food technologies-demonstrating Taiwan's latest achievements in technology commercialization and industrial innovation. More... |
| KoreaBIO seeks closer biotech ties with Taiwan 20 July, 2026 The Korea Biotechnology Industry Organization (KoreaBIO) called for closer bio supply chain cooperation between South Korea and Taiwan at BIO Asia-Taiwan 2026, highlighting the potential for deeper partnerships in biopharmaceutical manufacturing, digital health and startup investment. More... |
| BIO Asia-Taiwan 2026 Wraps Up with Record Participation, International Engagement 19 July, 2026 BIO Asia-Taiwan 2026, Asia's largest biotechnology gathering, concluded successfully today (19th of July), setting new benchmarks for participation and international engagement. The event underscored Taiwan's emergence as a globally connected biotechnology hub and a trusted partner to the international biotech industry. The conference also advanced regional collaboration by promoting the development of an Asian biotech ecosystem, fostering exchanges and creating new opportunities for future partnerships and business. More... |
| BIO Asia-Taiwan 2026 Regional Collaboration Forum: Closing the Final Gap to Establish Taiwan as an International Biotech Hub 18 July, 2026 The BIO Asia-Taiwan Regional Collaboration Forum was held on the 16th of July, part of BIO Asia-Taiwan 2026, held at the Nangang Exhibition Center, TaiNEX 1 & 2, Taipei, Taiwan, and brought together representatives from both established and emerging biotech nations to discuss how strengthened regional cooperation can accelerate the advancement of biotechnology across Asia and drive global innovation. Speakers agreed that biotechnology is a strategic priority requiring regional collaboration rather than competition. More... |
| National Cheng Kung University showcases medical innovations at BIO Asia-Taiwan 17 July, 2026 National Cheng Kung University presented on Thursday artificial intelligence-driven medical technologies at the 2026 BIO Asia-Taiwan expo. NCKU President Shen Meng-ru led the alliance. Members include labs, hospitals, industry partners, and research institutions from southern Taiwan looking to accelerate commercial adoption. More... |
| Vice President Bi-khim Hsiao Highlights Taiwan's Biotech Innovation Capacity at BIO AsiaÐTaiwan 2026, Showcasing End-to-End Strength from Research to International Markets 17 July, 2026 On the second day of the BIO Asia-Taiwan 2026 Exhibition (17th July), Taiwan Vice President Bi-khim Hsiao visited TaiNEX 1 to tour the venue and meet with industry representatives. Accompanied by organizers and representatives, she witnessed Taiwan's latest achievements in biotechnology, precision health, translational medicine, smart healthcare, technology development, and global industry expansion. Hsiao gained firsthand insight into Taiwan's growing biotech capabilities and its efforts to drive innovation and connect with international markets. More... |
| Taiwan's Biotech Ambition Gets a Presidential Signal as Vice President Hsiao Bi-khim Visits BIO Asia-Taiwan 2026 17 July, 2026 Vice President Hsiao Bi-khim's tour of the exhibition floor puts Taiwan's highest political office visibly behind an industry increasingly central to the country's next chapter of economic growth and global competitiveness. More... |
| BIO Asia-Taiwan 2026 Day 3 Round-Up: Biotech's Next Great Race Begins Where Discovery Ends 17 July, 2026 From in vivo CAR-T and supply-chain resilience to exosome standards, multi-omics and digital health, the closing conference programme delivered a revealing message: biotech's next competitive frontier lies not in discovering more, but in manufacturing, regulating, measuring and delivering innovation at scale. More... |
| BIO Asia-Taiwan 2026: Taiwan's Strength Lies in Building the Future of Medicine from Every Side 17 July, 2026 Taiwan's health ministry convened three forums on the three most expensive things medicine is about to produce. In every room, domestic companies explained why the world should buy from Taiwan. In every room, the ministry listening will have to buy it too. More... |
| Premier Cho Jung-tai Opens BIO Asia-Taiwan 2026 16 July, 2026 The official opening ceremony for BIO Asia-Taiwan 2026 was held today (16th of July) at Taipei Nangang Exhibition Center, TaiNEX 1. Centered on the theme "Asian Inspiration, Global Impact," this year's gathering has reached new heights in both scale and influence. Taiwan Premier Cho Jung-tai officially opened the event, presenting both BIO Asia Award and the Taiwan BIO Awards honors to individuals and organizations for their outstanding contributions to the sector. More... |
| Malaysia Secures RM7 Million Bioeconomy Deals with Taiwan Partners 16 July, 2026 Malaysia has secured three bioeconomy collaborations worth about RM7 million with Taiwanese partners, expanding commercial opportunities in insect technology, advanced biochar materials and biotechnology products. The agreements were formalized at the Malaysia Regional Collaboration Forum held alongside BIO Asia-Taiwan 2026, with Malaysia's participation led by the Malaysian Bioeconomy Development Corporation. More... |
| Precision Medicine's Next Decade Will Be Defined by Multi-Omics and AI 16 July, 2026 ACT Genomics Co-founder and CEO Dr. Hua Chien Chen explains how genomic profiling, AI and Asia's diverse clinical data could converge to make precision oncology more predictive, accessible and personalized by 2030. More... |
| The CDMO Scale Race Is Over. The Integration Race Has Begun 16 July, 2026 At BIO Asia-Taiwan 2026, Formosa Laboratories' Dr. Tom Tseng explains why the future of pharmaceutical outsourcing will be won by CDMOs that connect scientific expertise, ADC development and end-to-end manufacturing--not simply those with the largest capacity. More... |
| Drug Approval Opens the Door, but Commercial Execution Determines Who Wins 16 July, 2026 At BIO Asia-Taiwan 2026, Handa Pharmaceuticals Director Toshiyo Chen explains why differentiated innovation alone is not enough, and how mastering patents, market access and global commercial strategy will define the next generation of specialty pharma winners. More... |
| Taiwan's Regenerative Medicine Rise Is Redefining the Rules of Cell Therapy 16 July, 2026 Speaking with BioSpectrum Asia during BIO Asia-Taiwan 2026, Steminent's Ling-Mei Wang and Ching-Huai Ko explain why dedicated regulation, standardized manufacturing and intelligent automation will be critical to taking regenerative medicines from scientific promise to patients at scale. More... |
| From Science to Scale, Taiwan Stakes Its Claim on the Exosome Economy 16 July, 2026 On Day 2 of BIO Asia-Taiwan 2026, one room hosted a Nobel laureate on cell biology at nine in the morning and a cosmetics industry strategy session at three in the afternoon. Both were about exosomes. That is Taiwan's opportunity and Taiwan's problem, printed on a single day's schedule. More... |
| BIO Asia-Taiwan 2026 Opens, Bringing Together Global Biotech Leaders 15 July, 2026 BIO Asia-Taiwan 2026 opened today (15th of July) at the Taipei Nangang Exhibition Center, TaiNEX 1, bringing together policymakers, industry executives, and clinical research experts from Taiwan, Asia, and around the world. More... |
| BIO Asia-Taiwan 2026 Begins with a Bold Proposition: The Future of Biotech Will Be Written in Asia 16 July, 2026 The opening session of Asia's largest biotech gathering didn't ease in with pleasantries. It framed a thesis -- that the centre of gravity in drug discovery, regenerative medicine and biotech capital is shifting east -- and then handed the microphone to five people building the proof. More... |
| BIO Asia-Taiwan 2026: Taipei, the City That Won Over Global Biotech 15 July, 2026 Without intending to answer the same question, six global biotech leaders delivered the clearest endorsement yet of Taipei's growing influence on the future of life sciences. More... |
| BIO Asia-Taiwan 2026: The Business of Living Longer: Alex Zhavoronkov's Blueprint for Building a Longevity Company That Survives 15 July, 2026 Alex Zhavoronkov came to Taipei to answer the question the longevity industry keeps avoiding: not whether ageing can be treated, but who is going to pay for finding out. More... |
| Global and Local Strategies Intersect at BIO Asia-Taiwan 2026 Plenary on Medicine Resilience 15 July, 2026 On July 15, the 2026 BIO Asia-Taiwan International Conference kicked off in Taipei, uniting global biopharma elites to address pressing challenges in modern healthcare. A major highlight of the opening day was the plenary session themed "Medicine Resilience: Global & Local Perspectives". This session, one of three featured plenaries, brought together voices from public administration, multinational pharma companies, and strategic consultancy to dissect medicine resilience across both worldwide and local dimensions. More... |
| BIO Asia Award 2026 Honors Professor Masatoshi Hagiwara and AstraZeneca for Advancing Biotechnology Innovation and Public Health 13 July, 2026 The International Committee of BIO Asia-Taiwan today announced the recipients of the BIO Asia Award 2026. The Individual Award recognizes Professor Masatoshi Hagiwara, Professor at the Graduate School of Medicine, Kyoto University, Japan, for his pioneering contributions to translational medicine, innovative drug discovery, and biotechnology entrepreneurship. The Organization Award recognizes AstraZeneca for its leadership in pandemic response and its continued efforts to advance public health and healthcare innovation across Asia. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |